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ORIGINAL ARTICLE BACTERIOLOGYCollateral damage from oral ciproﬂoxacin versus nitrofurantoin in
outpatients with urinary tract infections: a culture-free analysis of gut
microbiotaA. J. Stewardson1,5, N. Gaïa2, P. François2, S. Malhotra-Kumar6,7, C. Delémont3, B. Martinez de Tejada4, J. Schrenzel2,
S. Harbarth1 and V. Lazarevic2, for the SATURN WP1 and WP3 Study Groups
1) Infection Control Program, 2) Service of Infectious Diseases, Genomic Research Laboratory, 3) Department of Primary Care, Community and Emergency
Medicine, 4) Department of Obstetrics and Gynaecology, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland, 5) Department of Medicine
(Austin Health), University of Melbourne, Heidelberg, Australia, 6) Department of Medical Microbiology and 7) Vaccine & Infectious Disease Institute, Universiteit
Antwerpen, Antwerp, BelgiumAbstractRecent treatment guidelines for uncomplicated urinary tract infections (UTIs) discourage ﬂuoroquinolone prescription because of collateral
damage to commensal microbiota, but the ecologic impact of alternative agents has not been evaluated by culture-free techniques. We
prospectively collected faecal samples at three time points from ambulatory patients with UTIs treated with ciproﬂoxacin or
nitrofurantoin, patients not requiring antibiotics and household contacts of ciproﬂoxacin-treated patients. We described changes in gut
microbiota using a culture-independent approach based on pyrosequencing of the V3–V4 region of the bacterial 16S rRNA gene. All
groups were similar at baseline. Ciproﬂoxacin had a signiﬁcant global impact on the gut microbiota whereas nitrofurantoin did not. The
end of ciproﬂoxacin treatment correlated with a reduced proportion of Biﬁdobacterium (Actinobacteria), Alistipes (Bacteroidetes) and four
genera from the phylum Firmicutes (Faecalibacterium, Oscillospira, Ruminococcus and Dialister) and an increased relative abundance of
Bacteroides (Bacteroidetes) and the Firmicutes genera Blautia, Eubacterium and Roseburia. Substantial recovery had occurred 4 weeks later.
Nitrofurantoin treatment correlated with a reduced relative proportion of the genus Clostridium and an increased proportion of the
genus Faecalibacterium. This study supports use of nitrofurantoin over ﬂuoroquinolones for treatment of uncomplicated UTIs to minimize
perturbation of intestinal microbiota.
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provided new insights into the collateral damage of antibioticMicrobiol Infect 2015; 21: 344.e1–344.e11
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.11.016therapy on composition and function of human microbiota [1]. By
perturbing the gut microbiota, antibiotics favour the selection and
ampliﬁcation of drug-resistant organisms already present in small
quantities, promote transfer of mobile resistance genes between
species and facilitate acquisition of drug-resistant organisms by
disabling the gut’s intrinsic colonization resistance capacity [1,2].
Moreover, antibiotic-mediated disturbance of gut microbiota may
promote conditions such as obesity, diabetes, inﬂammatory
bowel disease, allergies and asthma [3,4]. Such consequences
support the principle that therapeutic choices should consider
collateral damage in addition to curative effectiveness [5,6].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Stewardson et al. Collateral damage from ciproﬂoxacin 344.e2Recent international guidelines for the treatment of un-
complicated cystitis explicitly recognize the ecologic adverse
effects of antimicrobial agents as an important factor for
therapeutic choices [6]. Consequently, these guidelines
recommend avoidance of ﬂuoroquinolones in favour of older
agents such as nitrofurantoin, trimethoprim–sulfamethoxazole
and fosfomycin. However, while microbiomic studies have
demonstrated the impact of ciproﬂoxacin on the gut micro-
biome [7,8], the evidence regarding nitrofurantoin and other
older agents is predominantly culture based and therefore
provides information on only a small proportion of the gut
microbiota [9].
Our primary objective was to use high-throughput
sequencing to compare the effects of oral ciproﬂoxacin and
nitrofurantoin on the gut microbiota composition of nonhos-
pitalized patients with urinary tract infections (UTIs) compared
to patients without antibiotic exposure and household contacts
of patients receiving oral ciproﬂoxacin.MethodsStudy design
This study was nested within a prospective cohort study con-
ducted in ambulatory care clinics at the University of Geneva
Hospitals from January 2010 to August 2013 (trial registration
ISRCTN26797709). Approval was granted by the University of
Geneva Hospitals ethics committee (protocol 10-123). Subjects
provided informed consent.
Population and sampling
For this nested substudy, we selected four groups of ten adult
participants each from the above-mentioned outpatient cohort:
(a) UTI patients treated with ciproﬂoxacin 500 mg twice daily
(CP); (b) UTI patients treated with nitrofurantoin macrocrystals
100 mg twice daily (NF); (c) control patients without antibiotic
treatment (CRL); and (d) adult household contact for each
patient treated with ciproﬂoxacin (CTCP) as a second control
group with similar environmental exposures to CP. In addition,
we included two UTI patients treated with fosfomycin, one 3 g
dose (F), for more general analyses. Exclusion criteria for UTI
patients were treatment with systemic antibiotics within 2
months or hospitalization within 30 days; residence in a long-
term care facility; current urinary catheter; and renal trans-
plant or renal replacement therapy. The controls and house-
hold contacts received no antibiotics during the study period or
2 months before it.
All participants provided three stool samples: at baseline
(time point 1); at completion of antibiotic therapy (time point
2); and 4 weeks after the second sample (time point 3). ForClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infcontrol patients, the second sample was collected 7–10 days
after the baseline sample. Samples were kept on ice for a
maximum of 24 hours before being frozen at −80°C until DNA
extraction.
DNA extraction
A stool sample (about 100 μL) was mixed with 700 μL of the
lysis buffer (20 mM Tris, 2 mM EDTA pH8, 1% Tween-20, 2%
Triton X-100). The mixture was shaken in a NucleoSpin Bead
Tube containing ceramic beads (Macherey-Nagel, Düren, Ger-
many) for 4 minutes at maximum speed on a Vortex-Genie 2
with a horizontal tube holder (Scientiﬁc Industries, Bohemia,
NY, USA). The tube was centrifuged for 1 minute at 11 000g.
DNA was extracted from 500 μL of the supernatant using the
easyMag System (bioMérieux, Marcy l’Etoile, France). The
speciﬁc protocol with 50 μL silica and an elution volume of
50 μL was followed. Puriﬁed DNA was stored at −20°C.
PCR and pyrosequencing
The V3–4 region of the bacterial 16S rRNA gene, corre-
sponding to Escherichia coli 16S rDNA positions 358–784
(excluding primer sequences), was ampliﬁed. The PCRs
included 5 ng of DNA extract, 15 pmol of each forward primer
341F 50-NNNNNNNNTCCTACGGGNGGCWGCAG and
reverse primer 785R 50-NNNNNNNNTGACTACHVGGG-
TATCTAAKCC in 20 μL volume of MyTaq buffer containing
1.5 units MyTaq DNA polymerase (Bioline, London, UK) and
2 μL of BioStab PCR optimizer (II) (Sigma-Aldrich, Munich,
Germany) For each sample, the forward and reverse primers
had the same eight-nucleotide barcode sequence. The se-
quences of the primers speciﬁc to the 16S rRNA gene were as
described previously [10], except that an additional ambiguous
base was introduced in the reverse primer.
PCRs were carried out using the following parameters: initial
denaturation at 96°C for 2 minutes, followed by 30 cycles of
96°C for 15 seconds, 50°C for 30 seconds, 72°C for 60 sec-
onds. The presence of amplicons of interest and their con-
centration were determined by gel electrophoresis. About
20 ng amplicon DNA of each sample were pooled and the
amplicons of appropriate size were puriﬁed by preparative gel
electrophoresis. A 454 Library construction was done ac-
cording to standard 454 FLX Titanium protocols. The 454 GS
FLX Titanium Pyrosequencing was performed at LGC (Berlin,
Germany). Barcode sequences with no mismatches were
trimmed from the 50 ends of the sequence reads, and an
extension corresponding to the subject’s number and sampling
time was added to the sequence ID. Sequences with mis-
matches in the barcode sequence were removed. The resulting
ﬁle was deposited in MG-RAST under the accession number
4568378.3.ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 344.e1–344.e11
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Sequence ﬁltering was performed using the command ‘trim.seqs’
from the MOTHUR (version 1.32) software package [11]. We
removed sequences that met any of the following criteria: (a)
contained a mismatch in the barcode or contained more than
one mismatch in the 16S sequence of PCR primers; (b) con-
tained ambiguous bases; (c) were <250 or >600 nucleotides in
length after trimming of the reverse primer sequence; (d) con-
tained runs of 10 identical nucleotides; (e) had a minimum
quality score of <32 over a 50-nucleotide window. Any com-
plete or residual sequences of PCR primers at 50 of sequence
reads were removed after sequence alignment (MOTHUR
command ‘align.seqs’) against the Greengenes reference data-
base [12]. Primer sequences from the 30 ends were removed by
deleting 25 nucleotides for any sequence longer than 390 nu-
cleotides. Taxonomic assignments of 16S sequences were made
by operational taxonomic unit (OTU) picking with the Green-
genes reference database [12] as described previously [13] using
pipeline 6. Sequences were compared with the Greengenes
reference 16S rRNA gene database preclustered at 97% identity
(ﬁle gg_97_otus_4feb2011.fasta) [12] using BLASTN (-evalue 1e-
30-perc_identity 97-max_target_seqs 1) [14]. Minimum query
alignment coverage was set to 90%. Downstream analyses were
carried out using the taxonomic information of the matching full-
length 16S rRNA gene sequences.
To compare bacterial communities, we constructed a Bray-
Curtis [15] similarity matrix based on the square-root-
transformed relative abundance of OTUs. Principal co-
ordinates analysis of Bray-Curtis similarities was performed in
PRIMER-E (Primer-E Ltd., Plymouth, UK). Ecologic indices
(Shannon diversity, Simpson diversity and Chao 1 richness)
were calculated from OTU relative abundance in PRIMER-E.
We used paired (Wilcoxon signed rank) and nonpaired
(Wilcoxon rank sum) statistical tests to identify the taxa thatTABLE 1. Participant characteristics stratiﬁed by exposure group
Characteristic
Ciproﬂoxacin
(n [ 10)
Nitrofurantoin
(n [ 10)
Age, mean (SD) 38 (14.1) 31 (12.7)
Female 10 (100%) 10 (100%)
Body mass index category
Underweight 1 (10%) 3 (30%)
Normal range 4 (40%) 5 (50%)
Overweight 2 (20%) 2 (20%)
Obese 3 (30%) 0 (0%)
Vegetarian 0 (0%) 0 (0%)
Exposures in previous 12 months
Antibiotics 6 (60%) 5 (50%)
Hospitalization 1 (10%) 1 (10%)
Children in household 4 (40%) 4 (40%)
Diagnosis
Lower UTI 0 (0%) 10 (100%)
Upper UTI 10 (100%) 0 (0%)
Antibiotic duration, days, mean (SD) 10 (2.3) 5 (1.7)
UTI, urinary tract infection.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectchanged in proportion (a) within individuals at different visits,
(b) among household members at the same visit and (c) among
unrelated individuals at the same visit. These same tests were
used to compare groups of samples with regard to diversity and
richness.ResultsSubjects and sequencing
Baseline characteristics stratiﬁed by study group are presented
in Table 1. Faecal samples were taken at three occasions from
all subjects.
The number of the quality-ﬁltered pyrosequencing reads of
the 16S rDNA V3–4 amplicons were normalized to 893 per
sample, and the normalized data set was used for further ana-
lyses. The ﬁve samples with a coverage lower than 893
(Supplementary Table S1) were not included in the analyses
except for the inventory of OTUs.
Taxon abundance
The phyla Firmicutes and Bacteroidetes were identiﬁed in all
samples and had median relative abundance of 55.9% and 30.5%,
respectively. The phyla Actinobacteria, Tenericutes and Pro-
teobacteria were found in fewer samples (86%, 73% and 69%,
respectively) and had lower median relative abundance (0.67%,
0.34% and 0.17%, respectively). Other phyla (TM7, Cyanobac-
teria, Fusobacteria, Lentisphaerae, Synergistetes and Spiro-
chaetes) were detected in relatively few (1–17) samples.
Interestingly, the phylum Verrucomicrobia, represented by the
genus Akkermansia, was identiﬁed in 47% samples but showed
huge variation in relative abundance between and within in-
dividuals. In many individuals, the genus Akkermansia was under
the detection level, whereas seven subjects had at least oneFosfomycin
(n [ 2)
Control
(n [ 10)
Ciproﬂoxacin household
contact (n [ 10)
36 (4.9) 47 (7.1) 38 (13.7)
2 (100%) 8 (80%) 2 (20%)
0 (0%) 1 (10%) —
1 (50%) 1 (10%) —
1 (50%) 4 (40%) —
0 (0%) 4 (40%) —
0 (0%) 0 (0%) 1 (10%)
1 (50%) 2 (20%) 5 (50%)
0 (0%) 0 (0%) 2 (20%)
1 (50%) 8 (80%) —
2 (100%) — —
0 (0%) — —
single dose — —
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 344.e1–344.e11
CMI Stewardson et al. Collateral damage from ciproﬂoxacin 344.e4sample where the proportion of 16S sequences assigned to this
genus was >20%.
A total of 95 genera (Supplementary Table S1) were identiﬁed
in the data set. Sixteen of them had a median relative abundance
above zero. Of these genera, Bacteroides, ‘Clostridium’ (Lachno-
spiraceae), Coprococcus, Roseburia, ‘Ruminococcus’ (Lachnospir-
aceae) and Faecalibacterium were found in all 42 individuals
analysed (but not necessarily at all three time points).
Of 1461 OTUs identiﬁed, 24–241 OTUs were present in
individual samples (median 120) (Supplementary Table S1). No
OTUs were in all individuals, but an OTU assigned to Clos-
tridiales (OTU273775) was shared by all but one (control)
subject.
Differences in faecal bacterial communities related to
treatment
Results from pairwise PERMANOVA tests of Bray-Curtis sim-
ilarities of samples from the four patient groups at the three
time points are presented in Fig. 1. These demonstrate that at
baseline there was no statistically signiﬁcant difference in faecal
bacterial communities between the four groups.
Ciproﬂoxacin had a marked effect on the gut microbiota, as
demonstrated by both the signiﬁcant difference between the
second samples (end of antibiotic treatment) from the CP
group (CP2) and samples from other groups taken at any of the
three time points as well as the signiﬁcant differences found
between CP2 and both CP1 and CP3.
The difference between microbiota of the CP group and
other groups had diminished by 4 weeks after treatment. Six ofCP1 CP2 CP3 CTCP1 CTCP2
CP2 0.007
CP3 0.9 0.03
CTCP1 0.4 0.0001 0.04
CTCP2 0.3 0.0001 0.02 1
CTCP3 0.2 0.0001 0.02 0.9 1.0
CRL1 0.8 0.0007 0.04 0.6 0.5
CRL2 0.6 0.0006 0.06 0.5 0.4
CRL3 0.4 0.0004 0.03 0.6 0.4
NF1 0.6 0.0002 0.1 0.5 0.4
NF2 0.8 0.0007 0.1 0.1 0.08
NF3 0.5 0.0001 0.08 0.5 0.6
P <0.001
P <0.01
P <0.05
P <0.1
FIG. 1. Summary of results of PERMANOVA comparing the 12 groups of sam
with 9999 permutations was performed on Bray-Curtis similarity matrix ba
taxonomic units. p values for intergroup comparisons are indicated accord
household members of ciproﬂoxacin group; CRL, control group; NF, nitrofu
Sample 3 was collected about 28 days after sample 2.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infnine pairwise comparisons of CP3 samples with those from
other groups revealed statistically signiﬁcant differences and
these were rather weak (Fig. 1). The difference between CP1
and CP3 was not signiﬁcant.
In contrast to ciproﬂoxacin, nitrofurantoin treatment was
not associated with a statistically signiﬁcant global impact on the
gut microbiota, with the exception of the NF2–CTCP3 and the
above-mentioned NF2–CP2 comparison (Fig. 1). However,
several other comparisons between NF2 (at completion of
nitrofurantoin treatment) and NF3 (4 weeks after treatment)
samples with those from other groups were associated with p
values in the 0.05–0.1 range, which might suggest a weak global
effect of nitrofurantoin.
No signiﬁcant differences were found between any combi-
nation of samples collected from the two control groups (CRL
and CTCP).
Principal coordinate analysis of Bray-Curtis similarity matrix
of samples collected at the second visit shows that the micro-
biota from the ciproﬂoxacin group formed a somewhat sepa-
rate cluster, consistent with antibiotic mediated perturbation of
the intestinal microbiota (Fig. 2b). The ﬁrst principal coordinate
axis separates samples into two clusters: the right cluster is
formed by 21 samples, 17 of which (81%) correspond to CP-
treated individuals and/or subjects previously treated with an-
tibiotics. In the left cluster, more than two thirds (13/19) of
samples were from the subjects who were not previously
treated.
Using paired test (Wilcoxon signed-rank test), the greatest
number of signiﬁcant changes (13) at the genus level was foundCTCP3 CRL1 CRL2 CRL3 NF1 NF2
0.4
0.5 1
0.4 1 1
0.1 0.7 0.2 0.2
0.03 0.3 0.08 0.09 1
0.2 0.2 0.1 0.06 1 0.9
ples (four groups of individuals, three time points). PERMANOVA test
sed on the square-root-transformed relative abundance of operational
ing to the colour scale given at left. CP, ciproﬂoxacin group; CTCP,
rantoin group. Antibiotic exposure occurred between sample 1 and 2.
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 344.e1–344.e11
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344.e5 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIin the three comparisons including CP2 samples (CP1–CP2,
CP2–CP3 and CP2–CTCP2) (Supplementary Table S2). In
the remaining 12 pairwise comparisons, we found in total
eight signiﬁcant changes at the genus level. Using a nonpaired
statistical test (Wilcoxon rank sum test), the highest number of
indicator genera was found again for comparisons including
CP2 (four to nine hits), whereas the comparisons that did
not include CP2 revealed zero to two indicators. Similar
trends were observed at the OTU level (Supplementary
Table S2).Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectAt the genus level, whenever a signiﬁcant change was found
between CP2 and any of CP1, CP3 or CTCP2, as determined
using paired tests, the median values of CP2 were consistently
the highest or the lowest among all 12 groups of samples
(Fig. 3). The distributions of biomarkers, illustrated in Fig. 3,
showed that Biﬁdobacterium (Actinobacteria), Alistipes (Bacter-
oidetes), and four genera from Firmicutes (Faecalibacterium,
Oscillospira, Ruminococcus from the Ruminococcaceae family and
Dialister from Veillonellaceae) were signiﬁcantly reduced at the
end of ciproﬂoxacin treatment, but their proportion hadious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 344.e1–344.e11
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344.e7 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIrecovered by the end of the 4-week follow-up. In contrast, the
proportion of Bacteroides (Bacteroidetes) and the four Lach-
nospiraceae (Firmicutes) genera, i.e. Blautia, ‘Clostridium’, Eu-
bacterium and Roseburia increased at the end of the
ciproﬂoxacin treatment.
Nitrofurantoin treatment was associated with an increase in
the proportion of the genus Faecalibacterium, i.e. a trend
opposite to that of the ciproﬂoxacin treatment (Fig. 3 and
Supplementary Table S2). The other genus affected by nitro-
furantoin was Clostridium (Clostridiaceae), which decreased in
proportion at the end of the antibiotic treatment.
When patients treated with any antibiotic (ciproﬂoxacin,
nitrofurantoin or fosfomycin) over the study period were
compared to untreated subjects in PERMANOVA analysis,
statistically signiﬁcant differences in overall microbiota
composition were found at the end-of-treatment (p 0.004) and
4-week posttreatment sampling points (p 0.02) but not at
baseline (p 0.66). Conversely, the effect of previous antibiotic
treatment (deﬁned as antibiotic exposure between 2 and 12
months before the study regardless of the antibiotic class) was
observed at baseline (p 0.02) (Fig. 2A), but this difference was
lost at the second and third time points (p 0.10 and 0.80,
respectively), probably as a result of the dominant effect of the
new antibiotic exposure. At baseline, the genus Bacteroides had
higher relative abundance among the subjects who were
treated by antibiotics before the study period compared to
those who were not (median 24.4 vs. 4.6%; p 0.044, Wilcoxon
rank sum test).
Intra- and interindividual microbiota variation
As expected, gut microbiota similarity was higher within than
between individuals for the four groups of subjects. The dif-
ference between the intraindividual and interindividual similar-
ity was the smallest in the CP group (Fig. 4A). The CP1–2
intraindividual comparisons had a lower average Bray-Curtis
similarity than all other pairwise intraindividual comparisons
between the two time points in any group of subjects (Fig. 4B).
Principal coordinate analysis shows that samples clustered by
subject in each of the four groups (PERMANOVA global test
p < 0.0001) (Fig. 5). In the ciproﬂoxacin group, samples from
the same individual tended to be more distant from each other.
Microbiota similarities/differences unrelated to
treatment
According to PERMANOVA analysis, at baseline the faecal
microbiota was not signiﬁcantly inﬂuenced by age (age classes
compared were 18–30, 31–40, 41–50, >50 years; p > 0.35),
sex (p 0.58), BMI (BMI classes compared were <18.5, 18.5–25,
25–30, >30; p > 0.25), hospitalization or international travel in
the previous 12 months (p 0.32 and 0.36, respectively),Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcompanion animal exposure (p 0.39) or contact with meat
during food preparation (p 0.06).
At baseline, the average Bray-Curtis similarity was greater
for pairs of individuals from the same household (26.8%) than
for the pairs of unrelated individuals (23.1% in CP, 21.4% in
CTCP), but these differences were not signiﬁcant (p > 0.1).
Hierarchical clustering of samples based on the proportions of
OTUs or their presence/absence did not reveal any clustering
by household except for households 31 and 121
(Supplementary Fig. S1).
Diversity and richness
We found no signiﬁcant change in Shannon and Simpson di-
versity or in Chao 1 and OTU richness between the time pointious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 344.e1–344.e11
FIG. 5. Principal coordinates analysis of the four groups of samples. The ﬁrst, second and third time point sample of the same individual are rep-
resented by the same symbol in black (ﬁrst time point), dark gray (second time point) and light gray tones (third time point), respectively, and
surrounded by an oval.
CMI Stewardson et al. Collateral damage from ciproﬂoxacin 344.e8series of the four groups of samples. However, in the CP group,
the proportion of individuals in which Shannon diversity index
decreased at time point 2 relative to the baseline reached 78%
(7/9), which was greater than for any other group (NF 63%,
CRL 60%, CTCP 38%) (Supplementary Table S3). In the two
individuals in whom microbiota diversity increased during cip-
roﬂoxacin treatment we observed the following trends. (a) At
baseline, their gut microbiota was dominated by Turicibacter or
Dialister, the genera that were rare or virtually absent in other
CP-treated patients. (b) During treatment, their relative abun-
dance of Faecalibacterium increased, while in other individuals aClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infreduction occurred. (c) At the end of treatment, Bacteroides
were present at levels lower than in other individuals (Fig. 6).
The three individuals in whom Shannon diversity index
increased at the end of nitrofurantoin treatment had higher
baseline proportion of Akkermansia (21–36%) than had other
nitrofurantoin-treated subjects (0.1–5.5%). The microbiota of
one of these three subjects was also dominated by Dialister
(43%). However, it is not clear to what extent the observed
changes in diversity were caused by the use of antibiotics
because ﬂuctuations in diversity indices also occurred intra-
individually in the control group.ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 344.e1–344.e11
Before CP
treatment
End of CP
treatment
Reduced diversity at
the end of treatment
Increased diversity at
the and of treatment
Megamonas
Dialister
Bifidobacterium
Bacteroides
Parabacteroides
Prevotella
Alistipes
Turicibacter
Clostridium
Blautia
‘Clostridium’ (Lachnospiraceae)
Coprococcus
Eubacterium
Lachnobacterium
Lachnospira
Roseburia
‘Ruminococcus’ (Lachnospiraceae)
Faeclibacterium
Oscillospira
Ruminococcus
Other
CP_61 CP_7 CP_121 CP_142 CP_247 CP_4 CP_109CP_73 CP_31
FIG. 6. Relative abundance of genera in ciproﬂoxacin-treated patients. Only genera with relative abundance of >5% in at least one of 18 samples are
presented. Operational taxonomic units unassigned to a genus or assigned to low-abundance genera (<5% across all 18 samples) are summed to
represent the category ‘other’.
344.e9 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIDiscussionThe ﬁndings of this study provide evidence to support recent
international guidelines for the treatment of UTIs. These
guidelines favour ﬁrst-line use of older agents such as nitro-
furantoin over quinolones [6]. The rationale provided for this
approach was that these antimicrobial agents may have minimal
effects on normal faecal microbiota compared to ﬂuo-
roquinolones. Our study used a culture-independent approach
to conﬁrm this hypothesis.
Our ﬁndings are consistent with the pharmacokinetic pa-
rameters of these antibiotic agents. Nitrofurantoin is well
absorbed from the small intestine and rapidly excreted by the
kidneys while also being inactivated in most body tissues [16].
This, combined with the ﬁtness cost associated with nitro-
furantoin resistance [17], has been cited as the explanation for
the slow emergence of resistance and minimal collateral damage
caused by the drug [9,18]. In contrast, even a single dose of
ciproﬂoxacin results in high faecal concentrations of active drug
[19,20]. In the case of fosfomycin, approximately 18% of drug is
excreted unchanged in faeces after a single 3 g dose [21].
Our ﬁndings complement and expand on existing evidence.
Dethlefsen and colleagues [7,8] used high-throughput tech-
niques to explore the short- and long-term impact of cipro-
ﬂoxacin on the gut microbiome. Our study replicates their
ﬁnding that ciproﬂoxacin treatment results in a decreased
abundance of Faecalibacterium and Ruminococcus (both genera ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectphylum Firmicutes) and Alistipes (Bacteriodetes), as well as an
increased abundance of Bacteroides (Bacteriodetes). Both
studies also identiﬁed that some members of the Lachnospir-
aceae family (Firmicutes) increase while others decrease after
ciproﬂoxacin treatment, though at an overall family level, our
study demonstrated a signiﬁcant increase. Our study expands
on this work by recruiting patients with UTIs rather than
healthy volunteers—thus more closely describing clinical con-
ditions—and by including direct contrast with patients treated
with other antibiotics as well as household contacts and parallel
untreated control subjects.
Culture-dependent techniques have previously been used to
demonstrate that at a dose of 100 mg daily, nitrofurantoin has
minimal impact on aerobic intestinal microbiota compared to
trimethoprim–sulfamethoxazole and norﬂoxacin [22,23]. In a
cross-sectional study of elderly subjects, O’Sullivan et al. [24]
demonstrated that antibiotics that inhibit nucleic acid synthe-
sis have a more pronounced effect on gut microbiota compo-
sition. However, given that nitrofurantoin and ciproﬂoxacin
were both placed in this group (although nitrofurantoin has
multiple mechanisms of action [25]), comparison was not
performed. We are not aware of a previous study using high-
throughput sequencing techniques to speciﬁcally evaluate the
impact of nitrofuran derivatives on gut microbiota.
These ﬁndings have direct clinical signiﬁcance. Many of the
adverse effects speciﬁc to antibiotics are mediated by collateral
damage to commensal microbiota [2]. Antibiotic-mediatedious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 344.e1–344.e11
CMI Stewardson et al. Collateral damage from ciproﬂoxacin 344.e10perturbation of intestinal microbiota has been associated with
the development of Clostridium difﬁcile–associated diarrhoea
and colonization by vancomycin-resistant bacteria [26,27]. In
addition, animal models have been used to demonstrate that
changes in intestinal microbiota composition after antibiotic
exposure can result in increased susceptibility to enteric
infection [28].
We noted a wide range in the relative abundance of the
genus Akkermansia, from undetectable to >20%. This mucin-
degrading bacterium [29] has been recently found at unusually
high proportion (44.9% and 84.6%) in the gut microbiota from
two patients treated with broad-spectrum and extended anti-
biotherapy [30]. In our study, the high relative abundance of
Akkermansia was also found in untreated subjects.
Our study has several limitations. First, although the number
of individuals was greater than in many similar studies, it is still
low to draw ﬁrm conclusions about the effect of the antibiotics
used. Uncorrected p values were suggestive of an association
between the treatment and taxa changes. However, after
correction of the p values for multiple comparisons, most of
the differences in taxa proportions were no longer signiﬁcant
(data not shown). Second, individualized responses to antibiotic
treatments complicate the data analysis [31]. Analysing larger
cohorts may help to identify whether subjects may be grouped
into distinct types of response to antibiotic treatment and to
determine the factors critical to this response. Third, as a
pragmatic cohort study, baseline characteristics differed be-
tween all groups (including sex and body mass index) and
duration of treatment was longer among patients receiving
ciproﬂoxacin than patients receiving nitrofurantoin, potentially
confounding the causal relationship between the antimicrobial
agent and impact on intestinal microbiota [32,33]. Fourth, with
the sequencing depth used in this study, we were not able to
address the changes in very low-abundance taxa. Further
exploration of the impact of antibiotic therapy on gut micro-
biota using culturomics would offer complementary informa-
tion regarding minority populations and organisms other than
bacteria [34–37]. For instance, the selection of aerobic bacte-
ria, which represent a minor fraction of the gut microbiota, may
be achieved by culturing in the presence of oxygen. Finally, we
did not collect information regarding treatment outcomes or
adverse effects (e.g. antibiotic-associated diarrhoea) and
therefore cannot correlate these with antibiotic agent or
microbiota disturbance.
In summary, we found that ciproﬂoxacin had a signiﬁ-
cant—though largely reversible— impact on the intestinal
microbiota of patients with UTIs, whereas nitrofurantoin had
minimal impact. Our data suggest that a weak effect of cipro-
ﬂoxacin persists 1 month after treatment. These ﬁndings sup-
port the use of nitrofurantoin over ciproﬂoxacin for theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inftreatment of UTIs from the perspective of commensal micro-
biota ecology. The effect of nitrofurantoin on reducing the
proportion of Clostridium, some members of which are patho-
genic, and increasing Faecalibacterium, considered to have anti-
inﬂammatory properties [38], may even broaden the use of
this antibiotic for certain gastrointestinal disorders and
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